Markets

Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

Intercept Pharmaceuticals, Inc.ICPT was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $99.70 to $109.89 in the past one-month time frame.

None of the estimates for this stock were revised in the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday's action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Intercept Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

INTERCEPT PHARM Price

INTERCEPT PHARM Price | INTERCEPT PHARM Quote

A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is ICPT going up? Or down? Predict to see what others think: Up or Down

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ARBUTUS BIOPH (ABUS): Free Stock Analysis Report

INTERCEPT PHARM (ICPT): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABUS ICPT

Other Topics

Investing Stocks

Latest Markets Videos